Pascal Touchon, Atara Biotherapeutics CEO
November 9, 2023 07:13 AM EST
R&D
Cell/Gene Tx

Atara Bio­ther­a­peu­tic­s' stock drops near­ly 50% af­ter PhII tri­al fail in MS

Katherine Lewin

News Reporter

Atara Bio­ther­a­peu­tics’ cell ther­a­py flunked a Phase II study in pro­gres­sive mul­ti­ple scle­ro­sis, miss­ing the pri­ma­ry end­point as well as flu­id and imag­ing bio­mark­ers, …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times